DAX24.241 +0,8%ESt505.344 +1,0%Top 10 Crypto15,50 -6,1%Dow45.010 +1,1%Nas21.020 +0,6%Bitcoin101.104 +0,4%Euro1,1778 +0,1%Öl68,66 ±-0,0%Gold3.390 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 SAP 716460 NVIDIA 918422 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 Lufthansa 823212 BASF BASF11 Clara Technologies A3E4MS BYD A0M4W9 Volkswagen (VW) vz. 766403 Novo Nordisk A3EU6F Tesla A1CX3T Deutsche Bank 514000 Infineon 623100 DroneShield A2DMAA
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Zoll-Deal: DAX schließt höher -- US-Börsen letztlich fester - S&P 500 mit Rekord -- SAP mit Gewinnsprung - Umsatz unter Erwartungen -- Alphabet, Tesla, D-Wave, TUI, Micron, Clara Technologies im Fokus
Top News
Was passiert mit dem Kinderdepot, wenn das Kind volljährig wird? Was passiert mit dem Kinderdepot, wenn das Kind volljährig wird?
NVIDIA-Aktie im Rallymodus: NVIDIA-Chef Huang holt Google-Mitgründer Larry Page fast ein NVIDIA-Aktie im Rallymodus: NVIDIA-Chef Huang holt Google-Mitgründer Larry Page fast ein
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

AbbVie Aktie

Handeln
AbbVie Aktien-Sparplan
161,60 EUR +3,00 EUR +1,89 %
BMN
190,01 USD -0,49 USD -0,26 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.280,78 Mrd. EUR

KGV74,34Div. Rendite3,54%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J84E

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00287Y1091

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABBV

AbbVie Aktien News

DatumMeistgelesen
PR NewswireBOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project
PR NewswireAbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact
PR NewswireRefresh Releases First of its Kind Eye Drop for Dry Eyes
Wer­bungAbbVie-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireIchnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
PR NewswireAbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
PR NewswireAbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
PR NewswireU.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
PR NewswireAbbVie to Host Second-Quarter 2025 Earnings Conference Call
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireAbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
PR NewswireAbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
PR NewswireU.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
PR NewswireAbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
PR NewswireAbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
PR NewswireAbbVie Partners with Chicago Cubs on "Striking Out Cancer"
PR NewswireClass Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm
PR NewswireAbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio
PR NewswireAbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient
PR NewswireShareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV
PR NewswireAbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
PR NewswireAbbVie to Present at the Bank of America Securities Healthcare Conference
PR NewswireRINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
PR NewswireAbbVie Reports First-Quarter 2025 Financial Results
PR NewswireAbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines
PR NewswireAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
PR NewswireAbbVie to Host First-Quarter 2025 Earnings Conference Call
PR NewswireAbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
PR NewswireAllergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025
PR NewswireELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
PR NewswireSKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
PR NewswireAbbVie to Present at the Leerink Partners Global Healthcare Conference
PR NewswireAbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
PR NewswireAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
PR NewswireAbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
PR NewswireAbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireAllergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
PR NewswireAbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
PR NewswireU.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options
PR NewswireAllergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans

AbbVie News

AbbVie News: auf dieser Seite finden Sie alle AbbVie News und Nachrichten zur AbbVie Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbbVie News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbbVie News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.